

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 15, 2008  
(Date of earliest event reported)

**LABORATORY CORPORATION OF  
AMERICA HOLDINGS**

(Exact Name of Registrant as Specified in its Charter)

**DELAWARE**

(State or other jurisdiction  
of Incorporation)

**1-11353**

(Commission  
File Number)

**13-3757370**

(I.R.S. Employer  
Identification No.)

**358 SOUTH MAIN STREET,  
BURLINGTON, NORTH CAROLINA**

(Address of principal executive offices)

**27215**

(Zip Code)

**336-229-1127**

(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

On September 15, 2008, Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), announced that David P. King, Chief Executive Officer and William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the Bank of America 38<sup>th</sup> Annual Investment Conference in San Francisco, CA. LabCorp's presentation is planned for Wednesday, September 17, 2008 at 10:00 a.m. (Pacific Time).

Exhibits

99.1 Press Release dated September 15, 2008

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Laboratory Corporation of America Holdings  
(Registrant)

Date: September 15, 2008

By: /s/Bradford T. Smith  
Bradford T. Smith, Executive Vice President  
and Secretary

Laboratory Corporation of America  
358 South Main Street  
Burlington, NC 27215  
Telephone:(336) 584-5171

**FOR IMMEDIATE RELEASE**

**Investor/Media Contact: Eric Lindblom - 336-436-6739**

**Shareholder Direct: 800-LAB-0401**

**Company Information: [www.labcorp.com](http://www.labcorp.com)**

**LABCORP IS SCHEDULED TO PRESENT AT THE  
BANK OF AMERICA 38<sup>TH</sup> ANNUAL INVESTMENT CONFERENCE**

**Burlington, NC, September 15, 2008** — Laboratory Corporation of America<sup>®</sup> Holdings (LabCorp<sup>®</sup>) (NYSE: LH) today announced that David P. King, Chief Executive Officer and William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled to speak at the Bank of America 38<sup>th</sup> Annual Investment Conference in San Francisco, CA. LabCorp's presentation is planned for Wednesday, September 17, 2008 at 10:00 a.m. (Pacific Time).

A live audio webcast of the presentation will be available via the Company Web site at [www.labcorp.com](http://www.labcorp.com) and archived for replay.

**About LabCorp<sup>®</sup>**

Laboratory Corporation of America<sup>®</sup> Holdings, a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of \$4.1 billion in 2007, over 26,000 employees nationwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, National Genetics Institute, Inc., ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, DIANON Systems, Inc., US LABS, and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp conducts clinical trial testing through its Esoterix Clinical Trials Services division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at [www.labcorp.com](http://www.labcorp.com).

*Each of the above forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2007, and subsequent SEC filings.*